This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Erbitux Has Expanded Potential

This is a bonus story from Adam Feuerstein, whose biotech coverage usually runs only on RealMoney . We're offering it today to readers. To read Adam's commentary every day, click here for information on a free trial to RealMoney.

NEW ORLEANS -- ImClone Systems' (IMCL) cancer drug Erbitux, when added to radiation therapy, nearly doubles survival for patients with advanced head and neck cancer, according to results from a phase III study made public Saturday at the annual meeting of the American Society of Clinical Oncology (also known as ASCO).

It's not yet clear whether the positive data from this study will prompt ImClone and partner Bristol-Myers Squibb (BMY) to seek an expansion of Erbitux's label from the Food and Drug Administration. But the fact that Erbitux appears to help some patients with head and neck cancer live longer -- the most important test of a cancer drug's efficacy, generally speaking -- will likely convince oncologists to begin using the drug "off label" to treat this form of cancer. Erbitux is already approved and marketed as a treatment for advanced colon cancer.

There are about 40,000 people in the U.S. diagnosed each year with head and neck cancer. Of these, about 30% are currently treated with radiation alone and would therefore be candidates for the addition of Erbitux, according to a recent survey from investment bank SG Cowen. This equates to a $150 million market opportunity for ImClone, estimates Cowen, adding that sales could quadruple if doctors use Erbitux more broadly in head and neck cancer, just as they have started to do in colon cancer. (Cowen doesn't have an investment banking relationship with ImClone.)

The 424 patients enrolled in this phase III study were all diagnosed with advanced head and neck cancer that had not yet spread, or metastasized, to other parts of the body. About half the patients were treated with a combination of high-dose radiation plus Erbitux, the remaining half with high-dose radiation alone.

Patients receiving radiation and Erbitux had a median survival of 54 months, compared to a median survival of 28 months for patients receiving radiation alone. These results were statistically significant.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,653.40 +296.53 1.71%
S&P 500 2,046.37 +33.48 1.66%
NASDAQ 4,723.25 +78.9380 1.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs